Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

Oncol Rev · 2025 · PMC12331671 · PMID 40787089

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in a pre-specified subgroup analysis of patients with early planned use of docetaxel (the triplet therapy group), the difference in OS between the enzalutamide group and control group did not reach statistical significance (HR 0.82, 95% CI 0.63–1.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.